Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

13 Nov 2024 07:00

RNS Number : 9699L
Biome Technologies PLC
13 November 2024
 

This announcement contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

 

13 November 2024

 

Biome Technologies plc

("Biome", the "Company" or the "Group")

 

Trading Update

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today provides an unaudited trading update for the quarter ended 30 September 2024.

 

Group revenues for the nine months to 30 September 2024 were £3.2m, a 39% decrease over the same period last year (2023 Q3 YTD: £5.2m), but in line with management expectations.

 

The Group had a cash balance as at 30 September 2024 of £0.9m (30 September 2023: £0.9m), an unsecured loan from a related party of £63k and no bank debt.

 

Bioplastics Division

The division's revenues in 2024 Q3 were £0.7m, a 49% decrease compared to 2023 Q3 (2023 Q3: £1.3m). Revenues for nine months to 30 September 2024 were £2.7m, 38% behind the same period in the prior year (2023 Q3 YTD: £4.4m).

 

These lower revenues were primarily due to continued production and regulatory difficulties at two of the division's end customers which were discussed in the Interim Results, and which has subdued revenues throughout 2024. The current status with these two end customers is as follows:

 

1. The relevant certifying body for one end customer which operates in the coffee pod market required additional laboratory testing to be undertaken at short-notice. This testing was confirmatory and completed with a positive result as expected. The completion of formal certification is now expected in due course and revenue ramp-up is now expected to occur in 2025.

2. The regulatory difficulties at the other customer have now been overcome, the product range has been launched by the customer and revenues are now expected to build for Biome in 2025.

 

The technology behind Biome's products is protected by a portfolio of patents. In recent days, Novamont S.p.A., one of Biome's competitors, has indicated they are challenging the grant, by the European Patent Office (EPO), of one of Biome's recent patents. Biome has invested considerably in such technology and will defend its intellectual property vigorously.

 

RF Technologies Division

Revenues in the RF Technologies division for 2024 Q3 were £0.1m, compared to £0.3m in Q3 2023, a decrease of 59%. Revenues for the nine months to 30 September 2024 were £0.4m (2023 Q3 YTD: £0.8m).

 

The division successfully completed factory acceptance testing of a large project in August and this has since been shipped to the customer in preparation for installation. Revenue for this project will be recognised in 2024 Q4.

 

Three further projects of scale are currently works-in-progress in the factory in Southampton. Whilst it had been expected that all three of these would be delivered before the end of the current financial year, ongoing challenges with the delivery of components makes it more likely that only two of these will be delivered in the next six weeks with a consequential impact on the timing of revenue recognition.

 

A £193k contract for the supply of the Group's induction heating equipment for use in a UK regulated industry was signed in the third quarter. The design and build is well underway, with delivery and revenues expected in 2025.

 

Board

After over 17 years with the Company as Chairman, John Standen has indicated his wish and intention to retire and step down from the Board in the reasonably near term. The Directors are discussing various options in relation to the composition of the Board following Mr Standen's departure.

 

Group Outlook

The Bioplastics division continues to work to resolve the end-customer difficulties encountered in 2024 H1. Whilst good progress is being made, the unexpected additional testing required for certification described above has caused a delay to the anticipated ramp up for one of these customers. The Board has therefore made a further revision to its expectations of revenue and contribution from the Bioplastics division in 2024 Q4 and therefore for the full year.

 

The RF division is focused on delivering the large contracts won late last year and in 2024 H1. However, owing to ongoing difficulties in the supply chain for components, the Board anticipates a delay in delivery of one of the RF division's projects until 2025 Q1, impacting revenues in the final quarter of 2024 for the division.

 

As a result of the matters set out above, the Board has adjusted its revenue expectations for Biome in 2024, which are now expected to be below current market expectations with a consequential impact on profitability. Despite this, the Board is encouraged by the progress being made in both divisions to improve revenue run rates, albeit this improvement is now likely to occur in 2025.

 

-Ends-

 

 

For further information please contact:

Biome Technologies plc

Paul Mines, Chief Executive Officer

Donna Simpson-Strange, Company Secretary

www.biometechnologiesplc.com

 

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley/Lauren Wright (Nominated Adviser)

Kelly Gardiner/Tony Quirke (Sales and Corporate Broking)

www.allenbycapital.com

 

Tel: +44 (0) 20 3328 5656

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics ("Bioplastics") and Stanelco RF Technologies Limited ("RF Technologies").

 

Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The division's mission is to produce bioplastics that challenge the dominance of oil- based polymers.

 

RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

www.biometechnologiesplc.com www.biomebioplastics.com and www.thinkbioplastic.com www.stanelcorftechnologies.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKBBNOBDDQDD
Date   Source Headline
18th Apr 202310:49 amRNSCompletion of CLN Fundraising
17th Apr 202311:30 amRNSResult of General Meeting
31st Mar 202311:14 amRNSProposed issue of Convertible Loan Notes
25th Jan 20237:00 amRNSTrading Update
16th Nov 20227:00 amRNSBiome receives £282k grant
10th Nov 202211:05 amRNSSecond Price Monitoring Extn
10th Nov 202211:00 amRNSPrice Monitoring Extension
10th Nov 20227:00 amRNSTrading Update
18th Oct 20229:28 amRNSHolding(s) in Company
22nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:36 pmRNSPrice Monitoring Extension
22nd Sep 20222:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20222:00 pmRNSPrice Monitoring Extension
22nd Sep 20229:05 amRNSSecond Price Monitoring Extn
22nd Sep 20229:00 amRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSInterim Results
5th Sep 20227:00 amRNSGrant funding from Innovate UK
2nd Aug 20228:59 amRNSTrading Update - Replacement
2nd Aug 20227:00 amRNSTrading Update
20th Apr 202212:01 pmRNSResult of Annual General Meeting
20th Apr 20227:00 amRNSTrading Update
30th Mar 20222:48 pmRNSDirector/PDMR Shareholding
30th Mar 20227:00 amRNSNotice of AGM and 2021 Annual Report
24th Mar 20227:00 amRNSFinal Results 2021
27th Jan 20227:00 amRNSTrading Update
4th Jan 202210:33 amRNSFurther substantial contract win for RF Division
16th Dec 20218:41 amRNSContract
17th Nov 20217:00 amRNSTrading Update
9th Nov 202111:12 amRNSHolding(s) in Company
25th Oct 20217:00 amRNSUpdate re biodegradable tree shelters
15th Sep 20217:00 amRNSInterim Results
30th Jul 20219:47 amRNSDirector/PDMR Shareholding
29th Jul 20217:00 amRNSTrading Update
1st Jul 20219:05 amRNSSecond Price Monitoring Extn
1st Jul 20219:00 amRNSPrice Monitoring Extension
1st Jul 20217:00 amRNSTrading Update
30th Jun 20215:00 pmRNSTotal Voting Rights
7th Jun 202110:50 amRNSHolding(s) in Company
2nd Jun 20217:00 amRNSIssue of Equity and TVR
28th May 20217:00 amRNSAward under 2017 Long Term Incentive Plan
30th Apr 20215:00 pmRNSTotal Voting Rights
27th Apr 20214:25 pmRNSHolding(s) in Company
21st Apr 202110:51 amRNSHolding(s) in Company
21st Apr 202110:19 amRNSResult of Annual General Meeting
21st Apr 20217:00 amRNSTrading Update
9th Apr 20211:40 pmRNSPDMR Shareholding and transaction in own shares
1st Apr 202110:04 amRNSIssue of equity and Transaction in own shares
29th Mar 20217:00 amRNSNotice of AGM and Annual Report
25th Mar 20217:01 amRNSFinal Results 2020
25th Mar 20217:00 amRNSAppointment of New Non-Executive Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.